TLR9 and non-small cell lung carcinoma: Failure of a different TLR9 agonist to improve outcomes in advanced non-small cell lung cancer when added to chemotherapy suggests that the supportive immune response initiated by TLR9 agonists may firstly require release of tumour-associated antigens (Hirsh et al. 2011).